Esperion Therapeutics Inc (ESPR)

07:22 AM

Research Analysts Set Expectations for ESPR FY2025 Earnings - MarketBeat

07:22 AM

Jan 21, 2025

Esperion Therapeutics chief commercial officer sells $277 in stock By Investing.com - Investing.com Australia

Jan 21, 2025

Jan 21, 2025

Esperion Therapeutics CFO sells shares worth $20 By Investing.com - Investing.com South Africa

Jan 21, 2025

Jan 21, 2025

Esperion Therapeutics chief commercial officer sells $277 in stock - Investing.com India

Jan 21, 2025

Jan 21, 2025

Esperion Therapeutics CFO sells shares worth $20 - Investing.com India

Jan 21, 2025

Jan 19, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat

Jan 19, 2025

Jan 18, 2025

Barclays PLC Grows Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Jan 18, 2025

Jan 17, 2025

Esperion stock falls on higher operating expense forecast - MSN

Jan 17, 2025

Jan 12, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Jan 12, 2025

Jan 10, 2025

Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Jan 10, 2025

Jan 09, 2025

IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com

Jan 09, 2025

Jan 09, 2025

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - The Manila Times

Jan 09, 2025

Jan 09, 2025

Esperion to Host KOL Event on NEXLETOL, NEXLIZET Real-World Impact in Cholesterol Management - StockTitan

Jan 09, 2025

Jan 08, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript - MSN

Jan 08, 2025

Jan 03, 2025

Best 5 Penny Stocks With Great Financial Health (January 2025) - Investing.com

Jan 03, 2025

Jan 02, 2025

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian

Jan 02, 2025

Jan 02, 2025

Esperion to Present at J.P. Morgan Healthcare Conference: Showcasing Non-Statin Breakthroughs - StockTitan

Jan 02, 2025

Dec 31, 2024

FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm - AccessWire

Dec 31, 2024

Dec 29, 2024

Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreases By 16.5% - MarketBeat

Dec 29, 2024

Dec 26, 2024

ZTS: 3 Healthcare Innovators with Analyst-Endorsed Upside - StockNews.com

Dec 26, 2024

Dec 21, 2024

Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 21, 2024

Dec 20, 2024

ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Dec 20, 2024

Dec 20, 2024

Wellington Management Group LLP Grows Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 20, 2024

Dec 19, 2024

Cantor Fitzgerald Estimates ESPR FY2024 Earnings - MarketBeat

Dec 19, 2024

Dec 19, 2024

FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com

Dec 19, 2024

Dec 19, 2024

Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock By Investing.com - Investing.com Canada

Dec 19, 2024

Dec 18, 2024

Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock - Investing.com India

Dec 18, 2024

Dec 18, 2024

Cantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - MSN

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics issues $100M in new convertible notes - Investing.com

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics issues $100M in new convertible notes By Investing.com - Investing.com UK

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat

Dec 18, 2024

Dec 18, 2024

Esperion secures $150 million loan and $100 million notes By Investing.com - Investing.com UK

Dec 18, 2024

Dec 18, 2024

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewswire

Dec 18, 2024

Dec 18, 2024

Esperion Secures $250M in Strategic Financing, Restructures 80% of Debt in Major Deal - StockTitan

Dec 18, 2024

Dec 18, 2024

esperion stock faces uphill battle on bempedoic acid growth says Goldman - Investing.com Canada

Dec 18, 2024

Dec 17, 2024

Cantor Fitzgerald starts coverage on Esperion stock, highlights strong potential for NEXLETOL - Investing.com Canada

Dec 17, 2024

Dec 17, 2024

Cantor Fitzgerald Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat

Dec 17, 2024

Dec 17, 2024

Esperion announces $210M convertible debt financing - MSN

Dec 17, 2024

Dec 17, 2024

Esperion Therapeutics, Inc. announced that it expects to receive $42.5 million in funding - Marketscreener.com

Dec 17, 2024

Dec 15, 2024

Future of Heterozygous Familial Hypercholesterolemia Drug - openPR

Dec 15, 2024

Dec 14, 2024

Esperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Dec 14, 2024

Dec 13, 2024

Esperion Announces $210 Million Convertible Debt Financing - GlobeNewswire

Dec 13, 2024

Dec 13, 2024

Esperion Secures $210M Debt Restructuring Deal with Strategic Convertible Notes Offering - StockTitan

Dec 13, 2024

Dec 13, 2024

Esperion secures licensing deal for heart drugs in Israel By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

Esperion Partners with Neopharm to Commercialize NEXLETOL® - GlobeNewswire

Dec 12, 2024

Dec 12, 2024

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET - The Bakersfield Californian

Dec 12, 2024